Kepos Capital’s Emergent Biosolutions EBS Stock Holding History

Kepos Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-19,363	Closed	-$935K	–	335
2019 Q2	$935K	Sell	19,363 -28,856	-60%	-$1.38M	0.1%	170
2019 Q1	$2.44M	Hold	48,219	–	–	0.18%	150
2018 Q4	$2.86M	Hold	48,219	–	–	0.22%	125
2018 Q3	$3.17M	Hold	48,219	–	–	0.16%	128
2018 Q2	$2.44M	Buy	48,219 +38,085	+376%	+$1.98M	0.12%	148
2018 Q1	$534K	Buy	+10,134	New	+$505K	0.03%	218

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kepos Capital's EBS Position: Q3 2019 in Review

Kepos Capital sold out of Emergent Biosolutions (EBS) in Q3 2019, closing a stake of 19,363 shares — an estimated $935K sold.

Kepos Capital first reported a position in EBS in Q1 2018 and held it in 6 quarters. The position peaked at $3.17M in Q3 2018. 244 funds tracked by Wall St. Rank hold EBS as of Q3 2019.

Kepos Capital reported no remaining Emergent Biosolutions position as of Q3 2019 after selling out during the quarter.
Kepos Capital sold 19,363 Emergent Biosolutions shares in Q3 2019, an estimated $935K.
Kepos Capital first reported a position in Emergent Biosolutions in Q1 2018 and held it in 6 quarters.
Kepos Capital's Emergent Biosolutions position peaked at $3.17M in Q3 2018.
244 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2019.

Based on Kepos Capital's 13F filing for Q3 2019, filed 13 Nov 2019.